Almotriptan
| Clinical data | |
|---|---|
| Trade names | Axert, Almogran |
| Other names | LAS-31416; LAS31416 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a603028 |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Serotonin 5-HT1B, 5-HT1D, and 5-HT1F receptor agonist; Triptan; Antimigraine agent |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 70% |
| Protein binding | 35% |
| Metabolism | Liver |
| Elimination half-life | 3–4 hours |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H25N3O2S |
| Molar mass | 335.47 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Almotriptan, sold under the brand names Axert and Almogran among others, is a triptan medication used in the treatment of heavy migraine headache.[4][5][6][7]
Almotriptan was patented in 1992 and approved for medical use in 2000.[8] It was discovered and developed by Almirall-Prodesfarma.[7]
- ^ "Almotriptan tablet, film coated". DailyMed. Retrieved 17 February 2021.
- ^ "Axert- almotriptan malate tablet, coated". DailyMed. Retrieved 17 February 2021.
- ^ "Active substance: almotriptan" (PDF). List of nationally authorised medicinal products. Europeans Medicines Agency. 11 February 2021.
- ^ Rabasseda X (January 2001). "Almotriptan in the treatment of migraine". Drugs Today (Barc). 37 (1): 5–21. doi:10.1358/dot.2001.37.1.844180. PMID 12783094.
- ^ Cite error: The named reference
PalaciosRabassedaCastaner1999was invoked but never defined (see the help page). - ^ Cite error: The named reference
Holm_1999was invoked but never defined (see the help page). - ^ a b "Almotriptan". AdisInsight. 5 November 2023. Retrieved 28 July 2025.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 531. ISBN 9783527607495.